Overcome two major technical difficulties in the industry
Immune Cell Therapy (CAR-NK)
Cell Source: CAR-NK cells from healthy blood donors
In the R&D process, we have overcome the difficulties in the industry and prepared high-purity (98%), large-scale (amplification can be as high as 300,000 times) CAR-NK cells. One preparation of cells is enough for hundreds of patients to use.
With an independent intellectual property rights viral transduction system, the CAR-NK transduction rate can reach 90%, far exceeding the 10-20% level in the industry.
The capital market unanimously believes that CAR-NK from healthy blood donors is the right choice.
Comparison of Advantages and Disadvantages of Different NK Cell Sources
| Source | Advantages | Disadvantages |
| Healthy blood donors | High safety, strong killing ability | High difficulty in large-scale amplification, low gene modification efficiency |
| NK cell line (NK-92) | Tumor cell line, unlimited amplification | Products need irradiation, which reduces the therapeutic effect and has a carcinogenic risk |
| Induced pluripotent stem cells (iPSC) | iPSC can be amplified indefinitely, providing an unlimited source of NK cells | The process of iPSC differentiation into NK is complex, and the carcinogenic risk of iPSC cannot be ruled out |
| Umbilical cord blood NK cells (CB-NK) | High safety, providing a sufficient source of NK cells | Weak NK cell killing ability, carcinogenic risk cannot be ruled out |
Beijing Gene MiNK has technical barriers
Beijing Gene MiNK has solved many industry technical difficulties in the whole process and obtained 7 invention patents
CAR-NK cells can be mass-produced
Targeting the difficulties of NK cell amplification and low purity, our patented technology increases the NK cell amplification factor from hundreds of times to hundreds of thousands of times without using serum, and the NK purity is as high as 98%. This solves the difficulty that CAR-NK cells cannot be mass-produced.
Has independent intellectual property rights
Our company has screened out multiple tumor-specific targets and has independent intellectual property rights. In vivo and in vitro experiments have demonstrated its excellent specificity and can mediate excellent tumor killing effects.
Has an independently developed pseudotype virus packaging system
The difficulty of NK cell viral transduction is the biggest difficulty in the industry. Our company has independently developed a pseudotype virus packaging system, which has increased the transduction rate in the industry from less than 10% to an incredible 90%.
Improve the viral transduction rate of CAR-NK cells
Our company has invented a method to significantly improve the viral transduction rate of CAR-NK cells. This method ensures that CAR-NK cell products have very high product quality and ensures good therapeutic effects.
CAR-NK cell preparation patent technology
Our company's CAR-NK cell preparation process has a high technological content, and we have applied for a patent for this method to ensure our company's technological barriers.
Beijing Gene MiNK Biotechnology Invention Patents
Beijing Gene MiNK has invention patents in key aspects of NK and CAR-NK cell preparation.
Online Message
Please leave your needs and suggestions, and we will contact you as soon as possible!
Quick Navigation
Contact Information
Room 401, Unit 1, Building 2, No. 25, Jinghai Fourth Road, Beijing Economic and Technological Development Area, Beijing (Beijing Pilot Free Trade Zone, High-end Industrial Zone, Yizhuang Group)
Beijing Gene MiNK Biotechnology Co., Ltd